Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Lifevantage Corporation stock logo
LFVN
Lifevantage
$6.53
+4.1%
$6.90
$3.90
$15.00
$79.10M0.73220,075 shs56,480 shs
Lisata Therapeutics, Inc. stock logo
LSTA
Lisata Therapeutics
$1.67
-21.2%
$3.29
$1.64
$5.07
$19.31M0.7973,407 shs133,686 shs
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
$1.19
+2.6%
$2.31
$1.08
$3.08
$67.17M1.491.68 million shs11.75 million shs
Tharimmune, Inc. stock logo
THAR
Tharimmune
$1.94
-5.8%
$2.82
$0.95
$9.08
$73.20M1.431.48 million shs774,941 shs
7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Lifevantage Corporation stock logo
LFVN
Lifevantage
+4.15%+5.32%+4.82%+28.54%-52.89%
Lisata Therapeutics, Inc. stock logo
LSTA
Lisata Therapeutics
-21.23%-53.61%-51.45%-47.81%-36.98%
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
+2.59%-24.68%-43.33%-56.57%-50.00%
Tharimmune, Inc. stock logo
THAR
Tharimmune
-1.44%-11.97%-36.22%-39.59%+24.10%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Lifevantage Corporation stock logo
LFVN
Lifevantage
$6.53
+4.1%
$6.90
$3.90
$15.00
$79.10M0.73220,075 shs56,480 shs
Lisata Therapeutics, Inc. stock logo
LSTA
Lisata Therapeutics
$1.67
-21.2%
$3.29
$1.64
$5.07
$19.31M0.7973,407 shs133,686 shs
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
$1.19
+2.6%
$2.31
$1.08
$3.08
$67.17M1.491.68 million shs11.75 million shs
Tharimmune, Inc. stock logo
THAR
Tharimmune
$1.94
-5.8%
$2.82
$0.95
$9.08
$73.20M1.431.48 million shs774,941 shs
7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Lifevantage Corporation stock logo
LFVN
Lifevantage
+4.15%+5.32%+4.82%+28.54%-52.89%
Lisata Therapeutics, Inc. stock logo
LSTA
Lisata Therapeutics
-21.23%-53.61%-51.45%-47.81%-36.98%
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
+2.59%-24.68%-43.33%-56.57%-50.00%
Tharimmune, Inc. stock logo
THAR
Tharimmune
-1.44%-11.97%-36.22%-39.59%+24.10%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Lifevantage Corporation stock logo
LFVN
Lifevantage
2.00
Hold$5.00-23.43% Downside
Lisata Therapeutics, Inc. stock logo
LSTA
Lisata Therapeutics
1.67
Reduce$15.00798.20% Upside
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
1.50
ReduceN/AN/A
Tharimmune, Inc. stock logo
THAR
Tharimmune
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest LSTA, THAR, LFVN, and SPRO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/17/2026
Lisata Therapeutics, Inc. stock logo
LSTA
Lisata Therapeutics
Reiterated RatingSell (D-)
7/17/2026
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
Reiterated RatingSell (D-)
5/26/2026
Lifevantage Corporation stock logo
LFVN
Lifevantage
UpgradeHold (C-)Hold (C)
5/18/2026
Lisata Therapeutics, Inc. stock logo
LSTA
Lisata Therapeutics
UpgradeHold
5/15/2026
Lisata Therapeutics, Inc. stock logo
LSTA
Lisata Therapeutics
DowngradeBuyNeutral
5/7/2026
Lifevantage Corporation stock logo
LFVN
Lifevantage
DowngradeBuyHold$5.00
5/4/2026
Lifevantage Corporation stock logo
LFVN
Lifevantage
DowngradeHold (C)Hold (C-)
(Data available from 7/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Lifevantage Corporation stock logo
LFVN
Lifevantage
$228.53M0.36$1.15 per share5.70$2.75 per share2.37
Lisata Therapeutics, Inc. stock logo
LSTA
Lisata Therapeutics
$170K89.49N/AN/A$1.66 per share1.01
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
$66.80M1.03$0.16 per share7.62$1.05 per share1.13
Tharimmune, Inc. stock logo
THAR
Tharimmune
N/AN/AN/AN/A$0.68 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Lifevantage Corporation stock logo
LFVN
Lifevantage
$9.81M$0.4514.5110.05N/A2.94%23.89%12.47%9/3/2026 (Estimated)
Lisata Therapeutics, Inc. stock logo
LSTA
Lisata Therapeutics
-$16.59M-$1.86N/AN/AN/AN/A-103.54%-83.08%8/6/2026 (Estimated)
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
$8.57M$0.244.96N/AN/A24.90%35.58%24.95%8/11/2026 (Estimated)
Tharimmune, Inc. stock logo
THAR
Tharimmune
-$12.20M-$3.99N/AN/AN/AN/A-588.45%-264.41%N/A

Latest LSTA, THAR, LFVN, and SPRO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2026Q2 2026
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
-$0.17N/AN/AN/A$0.28 millionN/A
5/13/2026Q1 2026
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
-$0.18-$0.13+$0.05-$0.13$0.26 million$0.26 million
5/11/2026Q1 2026
Lisata Therapeutics, Inc. stock logo
LSTA
Lisata Therapeutics
N/A-$0.50N/A-$0.50N/AN/A
5/6/2026Q3 2026
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.16$0.12-$0.04$0.11$47.77 million$43.72 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.203.06%N/A44.44%3 Years
Lisata Therapeutics, Inc. stock logo
LSTA
Lisata Therapeutics
N/AN/AN/AN/AN/A
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
N/AN/AN/AN/AN/A
Tharimmune, Inc. stock logo
THAR
Tharimmune
N/AN/AN/AN/AN/A

Latest LSTA, THAR, LFVN, and SPRO Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/27/2026
Lifevantage Corporation stock logo
LFVN
Lifevantage
quarterly$0.052.12%6/1/20266/1/20266/15/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Lifevantage Corporation stock logo
LFVN
Lifevantage
N/A
1.96
1.04
Lisata Therapeutics, Inc. stock logo
LSTA
Lisata Therapeutics
N/A
4.23
4.23
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
N/A
10.50
10.50
Tharimmune, Inc. stock logo
THAR
Tharimmune
N/A
4.98
4.98

Institutional Ownership

CompanyInstitutional Ownership
Lifevantage Corporation stock logo
LFVN
Lifevantage
35.32%
Lisata Therapeutics, Inc. stock logo
LSTA
Lisata Therapeutics
8.94%
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
25.60%
Tharimmune, Inc. stock logo
THAR
Tharimmune
1.16%

Insider Ownership

CompanyInsider Ownership
Lifevantage Corporation stock logo
LFVN
Lifevantage
21.95%
Lisata Therapeutics, Inc. stock logo
LSTA
Lisata Therapeutics
9.60%
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
2.90%
Tharimmune, Inc. stock logo
THAR
Tharimmune
6.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Lifevantage Corporation stock logo
LFVN
Lifevantage
26012.62 million9.85 millionOptionable
Lisata Therapeutics, Inc. stock logo
LSTA
Lisata Therapeutics
309.11 million8.23 millionNot Optionable
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
15057.90 million56.22 millionOptionable
Tharimmune, Inc. stock logo
THAR
Tharimmune
237.73 million35.20 millionNot Optionable

Recent News About These Companies

Tharimmune Inc.
Tharimmune Approved as Super Validator on Canton Network
Tharimmune appoints Jacob Asbury as CFO
Tharimmune Appoints Jacob Asbury as New CFO
Crypto Company Creates Bizarre Drug

New MarketBeat Followers Over Time

Media Sentiment Over Time

Lifevantage stock logo

Lifevantage NASDAQ:LFVN

$6.53 +0.26 (+4.15%)
Closing price 07/24/2026 04:00 PM Eastern
Extended Trading
$6.39 -0.14 (-2.14%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. The company also provides anti-aging skin care products, including liquid collagen, facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, it offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website and network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. The company was founded in 2003 and is headquartered in Lehi, Utah.

Lisata Therapeutics stock logo

Lisata Therapeutics NASDAQ:LSTA

$1.67 -0.45 (-21.23%)
Closing price 07/24/2026 04:00 PM Eastern
Extended Trading
$1.72 +0.05 (+2.99%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

Spero Therapeutics stock logo

Spero Therapeutics NASDAQ:SPRO

$1.19 +0.03 (+2.59%)
Closing price 07/24/2026 04:00 PM Eastern
Extended Trading
$1.16 -0.03 (-2.52%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Tharimmune stock logo

Tharimmune NASDAQ:THAR

$1.94 -0.12 (-5.83%)
As of 07/24/2026

Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics; and Washington University in St. Louis for the rights to develop and commercialize technology related to multiple hybridomas and antibodies directed specifically towards human HER2. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.